For instance, our study found that patients with NSCLC who had lower PS scores before ICI treatment, high PD-L1 expression levels, combination therapy, and ICIs as first-line therapy were more likely to benefit from ICI treatment. Here, CD274 is linked to non-small cell lung carcinoma.